

# The regulation of nerve and blood vessel ingrowth in aneural and avascular intervertebral disc and articular cartilage

ALA Binch<sup>1</sup>, AK Cross<sup>1</sup>, CL Le Maitre<sup>1\*</sup>

## Abstract

### Introduction

This review will discuss the regulatory mechanisms of both innervation and vascularisation within normally aneural and avascular tissues, and how they may become altered in degeneration enabling new nerve and blood vessel formation which is hypothesised to be a source of pain.

### Conclusion

Normal intervertebral discs and articular cartilage are the largest aneural and avascular tissues in the human body yet during intervertebral disc degeneration and osteoarthritis these tissues become increasingly vascularised by small blood vessels and innervated by peptide containing sensory nerve fibres. The mechanism by which this process occurs remains largely unknown. Published data suggests that various factors present within the healthy tissues such as aggrecan, chondromodulin and semaphorins may act as repulsive barriers to neurite and endothelial cell invasion. During degeneration however, the synthesis of these molecules becomes disrupted, potentially leading to vascularisation and innervation of the tissue.

### Introduction

Innervation and vascularisation depend on the ability of growth cones on axons and endothelial tip cells on endothelial cells to guide them to their final destinations. This process is regulated by guidance molecules within the native tissue niche<sup>1,2</sup>. In

many tissues, these guidance molecules regulate the entry of nerves and blood vessels, yet in disease states, these mechanisms may become disrupted leading to the inappropriate entry of both nerves and blood vessels which can generate unwanted affects<sup>3,4,5,6</sup>. Studies have shown that typically aneural and avascular tissues such as the intervertebral disc (IVD) and articular cartilage (AC) become increasingly vascularised by small blood vessels and innervated by peptide containing sensory nerve fibres, which are hypothesised to elicit pain<sup>3,4,7,8,9,10</sup>. Normal IVDs and AC are suggested to be the largest aneural and avascular tissues within the human body, and are composed of proteins and matrix components which are inhibitory to the ingrowth of both nerve and blood vessels<sup>11,12,13</sup>.

This review aims to discuss the regulatory mechanisms of both innervation and vascularisation within normally aneural and avascular tissues, and how they may become altered in degeneration enabling new nerve and blood vessel formation, which is hypothesised to be a source of pain generation<sup>3,4,5,6</sup>.

### Discussion

The authors have referenced some of their own studies in this review. These referenced studies have been conducted in accordance with the Declaration of Helsinki (1964) and the protocols of these studies have been approved by the relevant ethics committees related to the institution in which they were performed. All human subjects, in these referenced studies, gave informed consent to participate in these studies.

### The intervertebral disc

The IVD is crucial for providing the structure and function of the spine, allowing movement and flexibility yet preventing hyperextension. IVDs are composed of three distinct anatomical regions; the nucleus pulposus (NP) which is constrained by the annulus fibrosus (AF) and cartilaginous end plates (CEPs)<sup>14</sup>. The highly specialized composition of the matrix within the IVD allows movement and offers resilience to compressive forces and loads.

### Articular cartilage

AC is a specialized connective tissue covering bony surfaces permitting smooth frictionless movement of synovial joints, and allowing the joint to withstand pressure and weight-bearing activities. Components of AC are very similar to those found within the IVD in that the dense extracellular matrix (ECM) is composed of predominantly type II collagen and proteoglycans which allows AC to resist tensile and compressive forces.

### Mechanisms of innervation and angiogenesis

In order to investigate how largely aneural and avascular tissues permit the entry and/or formation of nerves and blood vessels during disease states, this review will describe the factors present within healthy tissues which prevent nerve and blood vessel ingrowth.

Within both the IVD and AC, a number of repulsive factors exist which prevent nerve and endothelial cell ingrowth. In vitro proteoglycans, chondromodulin and semaphorins have been shown to inhibit neuronal and endothelial cell migration, all of which are expressed in vivo in the IVD and AC.

\*Corresponding author  
Email: c.lemaitre@shu.ac.uk

<sup>1</sup> Biomedical Research Centre, Sheffield Hallam University, Sheffield, UK.

## Prevention of innervation & vascularisation in Normal IVDs and AC

### *Proteoglycans and Glycosaminoglycans (GAGs)*

Proteoglycans have been widely investigated for their inhibitory properties towards both neurite outgrowth and endothelial cell adhesion and migration by a number of groups worldwide<sup>11,12,15</sup>. In vitro studies demonstrated aggrecan isolated from IVD<sup>11</sup> and AC<sup>12</sup> inhibits endothelial cell adhesion, migration and spreading. Thus suggesting that the loss of aggrecan, a natural anti-angiogenic factor during degeneration<sup>11</sup> may lead to unopposed entry of blood vessels into these tissues.

### *Chondromodulin*

Chondromodulin-I (ChM-I), a 25kDa glycoprotein is a novel growth regulating factor<sup>16</sup>, which is important in the maintenance of avascular regions of AC and IVDs. Studies by Hiraki et al., concluded that ChM-I was an inhibitor of endothelial cell tube formation<sup>17</sup>, in addition to this, recent studies by Miura et al., found that ChM-I inhibits chemotactic migration of endothelial cells by destabilising the actin cytoskeleton of lamellipodia extensions<sup>18</sup>.

Developmental studies in mice have identified that ChM-I expression is induced during the process of chondrogenesis and occurs in conjunction with production of type II collagen<sup>19</sup>. Shukunami et al., demonstrated that the level of ChM-I expression was substantially reduced in calcified zones of AC<sup>19</sup>. During gestational periods, immunohistochemistry studies identified a high percentage of ChM-I expression in ECM and chondrocytes of the IVD, which decreased after maturation, suggesting that ChM-I may regulate the degree of vascularisation that occurs during development<sup>20</sup>. Interestingly, immunopositivity of NP cells for ChM-I increased with degree of IVD degeneration<sup>20</sup> suggesting that ChM-I

attempts to reduce the threat of vascularisation during disease states.

### *Semaphorins*


Semaphorins are present within both healthy IVDs and AC<sup>13,21</sup>. They comprise a large family of axonal guidance molecules which are either membrane bound exerting their effects locally, or secreted and these can exert effects over a long distance<sup>22</sup>. Axonal guidance molecules signal via receptor complexes which ultimately regulate growth cone morphology via alterations to the actin cytoskeleton<sup>23,24,25</sup>. The Semaphorins share a highly conserved 500 amino acid 'Sema' domain followed by a PSI (plexin semaphorin integrin) domain, and are further subdivided into 8 classes based on their C-terminal structures<sup>26</sup>. Class 3 semaphorins are among the most well characterised members and are the only soluble form found within

vertebrates.

Semaphorins signal their response through two prominent semaphorin receptors; the neuropilins (NRP) and the plexins<sup>27,28,29,30</sup>. Whilst the majority of membrane bound semaphorins signal via plexins alone, class 3 semaphorins require the neuropilin as an obligate co-receptor generating a high affinity holoreceptor complex<sup>30,31</sup>.

### *Class 3 Semaphorins (Sema3)*

Sema3A has been studied for its role in axonal repulsion of both sensory and sympathetic neurons in chick<sup>32</sup> and humans<sup>33</sup>. De Wit et al., localised sema3A to axons and dendrites on cortical neurons together with NRP-1<sup>34</sup>. More recently sema3A has been identified within the IVD at both gene and protein level along with its receptors the neuropilins and plexins<sup>13</sup>. Tolofari et al., revealed that sema3A and sema3F were present




**Figure 1:** Schematic diagram of the regulation of axonal guidance of cells and their effects on directional growth concerning aneural and avascular tissue. The growth cone situated at the leading edge of the growing axon is able to sense and respond to cues within the environment. The growth cone is composed of lamellipodia which contains actin filaments and tensile structures composed of actin bundles known as the filopodia. In response to an attractive cue, F-actin is assembled and stabilised, whereas a repulsive cue would cause depolymerisation of F-actin, leading to the retraction of the filopodia.

Competing interests: None declared. Conflict of interests: None declared.  
All authors contributed to conception and design, manuscript preparation, read and approved the final manuscript.  
All authors abide by the Association for Medical Ethics (AME) ethical rules of disclosure.

within the AF of healthy IVD tissue, whereas sema3A was decreased significantly in this region of degenerated discs<sup>13</sup>. Thus suggesting that the presence of sema3A within the healthy AF prevents the ingrowth of both nerves and blood vessels<sup>13</sup>. Sema3F has more recently been localised to the outer layers of the retina where it is thought to have vasorepulsive properties towards retinal and choroidal capillaries, as levels are seen to deplete in patients with pathologic neovascularisation of the outer retina<sup>35</sup>. Class 3 semaphorins are unique in that sema3B and sema3C exert bifunctional activity, and are able to act as repulsive or attractive cues, and block the collapsing action of sema3A on dorsal root ganglia (DRG) neurons<sup>36</sup>.

#### *Interactions between semaphorins and the cytoskeleton*

During neuronal development, the axonal growth cone responds to various guidance cues within the surrounding environment. The growth cone selectively stabilises or destabilises the actin cytoskeleton in lamellipodia and filopodia to achieve directional growth<sup>37</sup> (Figure 1). The mechanism by which semaphorins interact with the cytoskeleton is a continued area of research, so far it has been reported that semaphorins alter the neuronal cytoskeleton by causing depolymerisation of F-actin<sup>23,24,38</sup>. Various signalling proteins are linked to semaphorin induced cytoskeletal changes within neuronal cells including the members of the Rho family of small GTP-binding proteins<sup>39,40,41,42</sup>, collapsin response mediator proteins (CRMPs) and intracellular protein kinases. Plexins within the holoreceptor complex generate an intracellular response to semaphorin binding, ultimately resulting in altered cytoskeletal dynamics and cell migration. Plexins have intrinsic GAP (GTPase activating protein) activity that activates R-Ras, a GTPase responsible for sustained integrin activation<sup>43,44</sup>. Activation of R-Ras enhances focal adhesion formation, cell adhesion and cell



**Figure 2:** Semaphorin receptors and their intracellular signalling pathways. Semaphorin receptors can cause activation of a number of different intracellular signalling pathways [155]. Semaphorins can regulate integrin function and cytoskeletal alterations via the activation of R-Ras GAP activity of plexins. The binding of semaphorins to holoreceptor complex formed by NRP ligand and plexin signal transducing element leads to the dissociation of FARP2 from plexinA1 leading to an increase in Rac activity, this allows the association of Rnd1 and

spreading, as well as favouring the activation of PI3K<sup>45</sup>. The binding of semaphorin to plexin receptors on the surface of growth cones therefore inactivates R-Ras which prevents integrin mediated cell adhesion, blocking downstream PI3K. Additionally, semaphorin-plexin interaction also activates other pathways such as Rac and Rho resulting in the depolymerisation of actin and endocytosis (Figure 2).

Ben-Zvi et al., demonstrated that sema3A application induced cell death of NGF, BDNF and NT3 dependant DRG neurons, and identified the mechanism was through the phosphorylation of c-jun/JNK pathway [100]. Repulsive agents arrest or completely collapse growth cones and neurite outgrowth<sup>38</sup>, as shown for sema3A which results in a loss of focal adhesions shortly followed by contraction of the cytoskeleton within endothelial cells<sup>46</sup>. A recent study by Yu et al., demonstrated sema3A inhibited both

migration and tube formation of HUVECs and significantly inhibited phosphorylation of the JNK and P38MAPK signalling pathway suggesting effects on vascularisation as well as innervation<sup>47</sup>. Neural connectivity and path finding is reliant on axonal guidance cues which either act as attractants or repellents on growth cones and endothelial tip cells during neovascularisation and innervation, causing the filopodia and lamellipodia to turn towards or away from the stimulus achieving directional growth (Figure1).

#### *Alternative roles of semaphorins in the regulation of angiogenesis*

Extensive studies of class 3 semaphorins have revealed their involvement in several non-neuronal processes such as angiogenesis<sup>35,48,49,50</sup>, organogenesis<sup>51,52,53</sup>, tumorigenesis<sup>50,54,55,56,57</sup>, immune cell function<sup>58</sup> and more recently a suggested role in osteoprotection<sup>59</sup> suggesting they may elicit a plethora of actions within these tissues.

Competing interests: None declared. Conflict of interests: None declared. All authors contributed to conception and design, manuscript preparation, read and approved the final manuscript. All authors abide by the Association for Medical Ethics (AME) ethical rules of disclosure.




### Angiogenic Factors

Several angiogenic growth factors have been localised to AC such as vascular endothelial growth factor (VEGF)<sup>60</sup>, fibroblastic growth factor (FGF-2)<sup>61</sup> and transforming growth factor beta (TGFβ)<sup>62</sup> yet AC and IVD are unique in that they remain largely avascular. The process of angiogenesis is complex and includes local degradation of the basement membrane, migration and proliferation of endothelial cells followed by the formation of new capillary sprouts. Various molecules have been studied for their potential anti-vascular properties such as elastase and proteinase inhibitors which ultimately prevent the degradation of the basement membrane. Tissue inhibitors of metalloproteinase-1 (TIMP-1) and TIMP-2 have also been speculated to be involved in preventing angiogenesis<sup>63</sup>, due to the inhibition of MMPs and thus decreasing matrix degradation.

In addition, although sema3A is classically known to repulse axonal growth cones<sup>32</sup> and cause apoptosis of NGF dependant sensory neurons<sup>64</sup> via the activation of JNK/c-jun signalling pathways<sup>65</sup>, sema3A has now been shown to have similar effects on endothelial cells<sup>46</sup>.

### Other regulators of innervation and angiogenesis

ECM molecules located in both AC and the IVD have been studied for their role in angiogenesis. Proteoglycans found within the IVD and AC ECM such as decorin are known to inhibit endothelial cell migration, tube formation and VEGF production<sup>15</sup>. Thrombospondin-I (TSP-I) exerts similar effects on endothelial cell formation<sup>63</sup>, and it is known that decorin binds to TSP-1 and potentiates the ability to block tube formation<sup>66</sup>. Various other anti-angiogenic molecules have been identified within AC and IVD such as troponin 1<sup>67</sup> angiostatin and endostatin<sup>68</sup>. Endostatin is a 20kDa c-terminal fragment of collagen type



**Figure 3:** Figure 3: Schematic diagram of the IVD in a non-degenerate and degenerate state. In a non-degenerate "healthy" IVD, both anabolic and catabolic processes are balanced, and various factors are present which help maintain the aneural and avascular environment of the IVD. These include aggrecan which is abundant in the healthy NP, along with semaphorins 3A and 3F which are localised to the outer AF. Elastin and chondromodulin are also present within the NP and AF and have been shown to have vasorepulsive roles towards endothelial cells. In a degenerate state, anabolic and catabolic processes are imbalanced in favour of catabolic processes which cause a decrease in matrix synthesis and an increase in matrix degradation, this process is enhanced by the action of proinflammatory cytokines known to regulate factors such as MMP's and ADAMTS enzymes which subsequently leads to a decrease in aggrecan and thus dehydration of the NP. Semaphorin 3A and 3F are significantly reduced within the degenerate outer AF which would create a permissive environment for the entry of both nerves and blood vessels.

XVIII, first identified by O Reiley et al., from haemangioendothelioma in mice<sup>68</sup> and has since been recognised for its ability to inhibit VEGF induced endothelial cell migration<sup>69</sup> and neovascularisation<sup>70</sup>.

Pufe et al., was the first group to identify the presence of endostatin within human cartilage<sup>71</sup>. Endostatin blocks angiogenesis by directly interacting with VEGFR2<sup>72</sup> which have been identified on the surface of hypertrophic and osteoarthritic chondrocytes<sup>73,74,75</sup>.

Endostatin has also been shown to inhibit VEGF induced activation of MMP-1 and -2 from endothelial cells<sup>76</sup> and AC<sup>77,78</sup>.

### Disease mechanisms which lead to innervation and angiogenesis

There are various mechanisms within the normal IVD and AC which are thought to prevent the ingrowth of nerves and blood vessels. During disease states, these processes become disrupted which is suspected to allow the inappropriate entry of both nerves and blood vessels; ultimately leading to pain generation.

### Characteristic changes in disease

The human IVD and AC undergo major biochemical alterations during degeneration which cause disruption to matrix homeostasis leading to the decreased synthesis of both collagen type II and proteoglycans, which are key features of degenerative processes<sup>79,80</sup>. Additionally,



components which inhibit nerve and blood vessel ingrowth such as chondromodulin and semaphorins are also lost during degeneration which may lead to the innervation and vascularisation of the tissue<sup>13,20</sup>.

#### *Upregulation of matrix degrading enzymes*

Early stages of degeneration are characterised by the imbalance of catabolic and anabolic processes<sup>81</sup>, which ultimately results in the loss of matrix components vital to the structure and function of both IVD and AC tissues. Cytokines, particularly IL-1 $\beta$  and TNF $\alpha$  have been implicated to mediate the destruction in OA<sup>82,83</sup> and IVD degeneration<sup>84,85,86,87,88,89,90,91,92,93</sup>. These pro-inflammatory cytokines are known for their potent activity in increasing the production of matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin-motif (ADAMTS) from chondrocytic cells of AC and IVD<sup>85,86,94,95</sup>, leading to loss in normal matrix, facilitating the unimpaird ingrowth of nerves and blood vessels.

#### *Loss of proteoglycans and collagen type II*

The loss of proteoglycans and collagen type II is one of the earliest changes identified during degeneration, characterised by a switch in the type of proteoglycans and collagens synthesised. A decrease in aggrecan production is replaced by biglycan, decorin and versican<sup>96,97</sup>, along with the switch in production of collagen from type II to type I<sup>98</sup> leaving the tissue dehydrated and unable to withstand compressive loads and forces.

Proteoglycans are known for their inhibitory effects on neurite ingrowth and so their presence within the healthy IVD and AC is pivotal not only for the structure and function of the tissues, but also in regulating the aneural and avascular environment<sup>11</sup>. As shown by Johnson et al., and Bara et al., aggrecan derived from the IVD and AC is able to prevent cell adhesion and migration<sup>11,12</sup>, thus endothelial

cell adhesion would be prevented in the normal disc and so NGF expressed by endothelial cells would not be able to enhance the survival of incoming neuronal cells.

#### *Altered expression of inhibitory factors during degeneration*

ChM-I is a matrix component of both AC and IVD known for maintaining the avascular environment, however during degeneration ChM-I is seen to decrease. Hayami et al., identified the presence of ChM-I within healthy avascular adult AC, and found that in early OA, levels of ChM-I decreased slightly within the superficial zone, yet in advanced OA, ChM-I was decreased in all zones of AC alongside an increase in the number of VEGF expressing chondrocytes<sup>99</sup>.

Immunohistochemistry identified the localisation of incoming vascular endothelial cells within close proximity to VEGF expressing cells where there was lowered expression of ChM-I.

Semaphorins are thought to act as a barrier to neural and vascular ingrowth within healthy IVD and AC; this was suggested by Tolofari et al., who identified the presence of sema3A within the outer AF in healthy IVDs<sup>13</sup>.

During degeneration however, sema3A was significantly decreased within the AF and immunopositivity increased around cell clusters within the degenerate NP. Invading nerves and blood vessels can be seen entering regions within the outer AF<sup>13</sup>, suggesting that during degeneration, the loss of the inhibitory semaphorin barrier allows inappropriate vascularisation and innervation.

Okubo et al., also identified an overexpression of sema3A within osteoarthritic cloned chondrocytes a feature associated with degeneration. The increase in sema3A within AC was also shown to inhibit VEGF induced chondrocyte migration by competitive binding to NRP-1<sup>21</sup>.

#### *Inappropriate entry of nerves and blood vessels*

Pain felt by patients with OA is sometimes described as a burning pain, which is characteristic of the pain generated by the presence of fine unmyelinated nerve fibres<sup>100</sup>. Mechanisms concerning the entry of nerve and blood vessels into usually avascular and aneural tissue is still incompletely understood. Various studies have reported the presence of cytokines: IL-1 $\beta$  and TNF $\alpha$ , which are potent pro-inflammatory mediators present in IVD degeneration<sup>84,85,88,89,92,101,102,103</sup> and OA<sup>82</sup> which cause disruption to the ECM composition.

The majority of sensory nerve fibres within IVDs and AC are associated with blood vessels, as they grow along endothelial cells after angiogenesis has occurred<sup>104,105</sup>. Freemont et al., were the first to identify the presence of small unmyelinated peptide-containing sensory nerve fibres and microvessels within degenerate lumbar IVDs of patients experiencing pain<sup>4</sup>.

Later studies by the same group<sup>3</sup> observed microvessels expressing the neurotrophic factor NGF, whilst accompanying nerves expressed the high affinity receptor Trk A. Early observations identified neuronal growth alongside endothelial cells. Neurotrophic factors NGF, BDNF and NT3 and their receptors, the tyrosine kinases are involved in the survival of neurons and have been identified at gene and protein level within IVD and AC<sup>106,107,108,109,110,111,112</sup>; Recently Krock et al., demonstrated NGF and BDNF protein production by IVD organ cultures from degenerate disc were significantly higher than those from healthy discs<sup>113</sup> this agreed with previous studies which had shown increased levels of NGF expression in surgical degenerate IVD compared to postmortem tissues<sup>111,114</sup>.

In contrast Purmessur et al., found high levels of NGF and BDNF within IVDs, with no significant changes between regions of the IVD and disease severity<sup>109</sup> demonstrating this area requires further investigation.

Competing interests: None declared. Conflict of interests: None declared. All authors contributed to conception and design, manuscript preparation, read and approved the final manuscript. All authors abide by the Association for Medical Ethics (AME) ethical rules of disclosure.



Inflammatory cytokines present within the degenerate IVD and AC have been shown to regulate the expression of these neurotropic factors<sup>106,108,109,112,115</sup>. NGF dependant neurons are known to synthesise pain related peptides, substance P and calcitonin gene related peptide (CGRP)<sup>10,114,116,117,118</sup> leading to pain sensitisation, and these have been shown to be regulated by cytokines<sup>109</sup>.

### Conclusion

To conclude, there are numerous native molecules which exert inhibitory effects towards neural and vascular ingrowth within healthy non-degenerate IVDs and AC (Figure 3). Whilst during degeneration the depletion of these inhibitory factors and production of nerve and endothelial growth factors (Figure 3) leads to the inappropriate entry of nerves and blood vessels.

### Authors' contribution

ALA Binch contributed to study design and drafted the manuscript. Alison K Cross and Christine L Le Maitre conceived the topic of the review, secured funding and critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

### Abbreviations

AC: Articular Cartilage  
 ADAMTs: A Disintegrin and Metalloproteinase with Thrombospondin motifs  
 AF: Annulus Fibrosus  
 BDNF: Brain Derived Neurotrophic Factor  
 CEP: Cartilaginous End Plate  
 CGRP: Calcitonin Gene Related Peptide  
 ChM-I: Chondromodulin-I  
 CRMPs: Collapsin Response Mediator Proteins  
 DRG: Dorsal Root Ganglia  
 ECM: Extracellular Matrix  
 FGF-2: Fibroblast Growth Factor  
 GAGs: Glycosaminoglycans  
 GAP: GTPase Activating Protein  
 HUVEC: Human Umbilical Vein Endothelial Cells  
 IL-1: Interleukin 1

IVD: Intervertebral Disc  
 MMP: Matrix Metalloproteinase  
 NGF: Nerve Growth Factor  
 NP: Nucleus Pulposus  
 NRP-1: Neuropilin 1  
 NT3: Neurotrophin 3  
 OA: Osteoarthritis  
 PSI: Plexin Semaphorin Integrin  
 Sema3: Class 3 Semaphorin  
 TGFβ: Transforming Growth Factor Beta  
 TIMP: Tissue Inhibitor of Metalloproteinase  
 TNF: Tumour Necrosis Factor  
 Trk: Tropomyosin Kinase  
 TSP-I: Thrombospondin-I  
 VEGF: Vascular Endothelial Growth Factor  
 VEGFR2: Vascular Endothelial Growth Factor Receptor 2

### References

- Gerhardt H, Golding M, Fruttiger M, Ruhrberg C, Lundkvist A, Abramsson A, Jeltsch M, Mitchell C, Alitalo K, Shima D, Betsholtz C. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. *J Cell Biol.* 2003 Jun 23;161(6):1163-77.
- Gerhardt H, Ruhrberg C, Abramsson A, Fujisawa H, Shima D, Betsholtz C. Neuropilin-1 is required for endothelial tip cell guidance in the developing central nervous system. *Dev Dyn.* 2004 Nov;231(3):503-9.
- Freemont AJ, Watkins A, Le Maitre C, Baird P, Jeziorska M, Knight MT, Ross ER, O'Brien JP, Hoyland JA. Nerve growth factor expression and innervation of the painful intervertebral disc. *J Pathol.* 2002 Jul;197(3):286-92.
- Freemont AJ, Peacock TE, Goupille P, Hoyland JA, O'Brien J, Jayson MI. Nerve ingrowth into diseased intervertebral disc in chronic back pain. *Lancet.* 1997 Jul 19;350(9072):178-81.
- Melrose J, Roberts S, Smith S, Menage J, Ghosh P. Increased nerve and blood vessel ingrowth associated with proteoglycan depletion in an ovine anular lesion model of experimental disc degeneration. *Spine (Phila Pa 1976).* 2002 Jun 15;27(12):1278-85.
- Ashraf S, Wibberley H, Mapp PI, Hill R, Wilson D, Walsh DA. Increased vascular penetration and nerve growth in the meniscus: A potential source of pain in osteoarthritis. *Ann Rheum Dis.* 2011 Mar;70(3):523-9.
- Suri S, Gill SE, Massena de Camin S, Wilson D, McWilliams DF, Walsh DA. Neurovascular invasion at the osteochondral junction and in osteophytes in osteoarthritis. *Ann Rheum Dis.* 2007 Nov;66(11):1423-8.
- Beaman DN, Graziano GP, Glover RA, Wojtys EM, Chang V. Substance P innervation of lumbar spine facet joints. *Spine (Phila Pa 1976).* 1993 Jun 15;18(8):1044-9.
- Brown MF, Hukkanen MV, McCarthy ID, Redfern DR, Batten JJ, Crock HV, Hughes SP, Polak JM. Sensory and sympathetic innervation of the vertebral endplate in patients with degenerative disc disease. *J Bone Joint Surg Br.* 1997 Jan;79(1):147-53.
- Wojtys EM, Beaman DN, Glover RA, Janda D. Innervation of the human knee joint by substance-P fibers. *Arthroscopy: The Journal of Arthroscopic and Related Surgery.* 1990;6(4):254-63.
- Johnson WE, Caterson B, Eisenstein SM, Roberts S. Human intervertebral disc aggrecan inhibits endothelial cell adhesion and cell migration in vitro. *Spine (Phila Pa 1976).* 2005 May 15;30(10):1139-47.
- Bara JJ, Johnson WE, Caterson B, Roberts S. Articular cartilage glycosaminoglycans inhibit the adhesion of endothelial cells. *Connect Tissue Res.* 2012;53(3):220-8.
- Tolofari SK, Richardson SM, Freemont AJ, Hoyland JA. Expression of semaphorin 3A and its receptors in the human intervertebral disc: Potential role in regulating neural ingrowth in the degenerate intervertebral disc. *Arthritis Res Ther.* 2010;12(1):R1.
- Bogduk N. Clinical anatomy of the lumbar spine and sacrum. Churchill Livingstone; 1997.
- Grant DS, Yenisey C, Rose RW, Tootell M, Santra M, Iozzo RV. Decorin suppresses tumor cell-mediated angiogenesis. *Oncogene.* 2002 Jul 18;21(31):4765-77.
- Hiraki Y, Inoue H, Iyama K, Kamizono A, Ochiai M, Shukunami C,

Competing interests: None declared. Conflict of interests: None declared.  
 All authors contributed to conception and design, manuscript preparation, read and approved the final manuscript.  
 All authors abide by the Association for Medical Ethics (AME) ethical rules of disclosure.





- Iijima S, Suzuki F, Kondo J. Identification of chondromodulin I as a novel endothelial cell growth inhibitor. purification and its localization in the avascular zone of epiphyseal cartilage. *J Biol Chem.* 1997 Dec 19;272(51):32419-26.
17. Hiraki Y, Kono T, Sato M, Shukunami C, Kondo J. Inhibition of DNA synthesis and tube morphogenesis of cultured vascular endothelial cells by chondromodulin-I. *FEBS Lett.* 1997 Oct 6;415(3):321-4.
18. Miura S, Mitsui K, Heishi T, Shukunami C, Sekiguchi K, Kondo J, Sato Y, Hiraki Y. Impairment of VEGF-A-stimulated lamellipodial extensions and motility of vascular endothelial cells by chondromodulin-I, a cartilage-derived angiogenesis inhibitor. *Exp Cell Res.* 2010 Mar 10;316(5):775-88.
19. Shukunami C, Iyama K, Inoue H, Hiraki Y. Spatiotemporal pattern of the mouse chondromodulin-I gene expression and its regulatory role in vascular invasion into cartilage during endochondral bone formation. *Int J Dev Biol.* 1999 Jan;43(1):39-49.
20. Takao T, Iwaki T, Kondo J, Hiraki Y. Immunohistochemistry of chondromodulin-I in the human intervertebral discs with special reference to the degenerative changes. *Histochem J.* 2000 Sep;32(9):545-50.
21. Okubo M, Kimura T, Fujita Y, Mochizuki S, Niki Y, Enomoto H, Suda Y, Toyama Y, Okada Y. Semaphorin 3A is expressed in human osteoarthritic cartilage and antagonizes vascular endothelial growth factor 165-promoted chondrocyte migration: An implication for chondrocyte cloning. *Arthritis Rheum.* 2011 Oct;63(10):3000-9.
22. Kolodkin AL. Semaphorins: Mediators of repulsive growth cone guidance. *Trends Cell Biol.* 1996 Jan;6(1):15-22.
23. Fan J, Mansfield SG, Redmond T, Gordon-Weeks PR, Raper JA. The organization of F-actin and microtubules in growth cones exposed to a brain-derived collapsing factor. *J Cell Biol.* 1993 May;121(4):867-78.
24. Fournier AE, Nakamura F, Kawamoto S, Goshima Y, Kalb RG, Strittmatter SM. Semaphorin3A enhances endocytosis at sites of receptor-F-actin colocalization during growth cone collapse. *J Cell Biol.* 2000 Apr 17;149(2):411-22.
25. Dent EW, Barnes AM, Tang F, Kalil K. Netrin-1 and semaphorin 3A promote or inhibit cortical axon branching, respectively, by reorganization of the cytoskeleton. *J Neurosci.* 2004 Mar 24;24(12):3002-12.
26. Semaphorin Nomenclature Committee. Unified nomenclature for the semaphorins/collapsins. *Cell.* 1999 May 28;97(5):551-2.
27. He Z, Tessier-Lavigne M. Neuropilin is a receptor for the axonal chemorepellent semaphorin III. *Cell.* 1997 Aug 22;90(4):739-51.
28. Kolodkin AL, Levengood DV, Rowe EG, Tai YT, Giger RJ, Ginty DD. Neuropilin is a semaphorin III receptor. *Cell.* 1997 Aug 22;90(4):753-62.
29. Chen H, Chedotal A, He Z, Goodman CS, Tessier-Lavigne M. Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins sema E and sema IV but not sema III. *Neuron.* 1997 Sep;19(3):547-59.
30. Tamagnone L, Artigiani S, Chen H, He Z, Ming GI, Song H, Chedotal A, Winberg ML, Goodman CS, Poo M, Tessier-Lavigne M, Comoglio PM. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. *Cell.* 1999 Oct 1;99(1):71-80.
31. Takahashi T, Fournier A, Nakamura F, Wang LH, Murakami Y, Kalb RG, Fujisawa H, Strittmatter SM. Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. *Cell.* 1999 Oct 1;99(1):59-69.
32. Luo Y, Raible D, Raper JA. Collapsin: A protein in brain that induces the collapse and paralysis of neuronal growth cones. *Cell.* 1993 Oct 22;75(2):217-27.
33. Kolodkin AL, Matthes DJ, Goodman CS. The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. *Cell.* 1993 Dec 31;75(7):1389-99.
34. De Wit J, De Winter F, Klooster J, Verhaagen J. Semaphorin 3A displays a punctate distribution on the surface of neuronal cells and interacts with proteoglycans in the extracellular matrix. *Mol Cell Neurosci.* 2005 May;29(1):40-55.
35. Buehler A, Sitaras N, Favret S, Bucher F, Berger S, Pielen A, Joyal JS, Juan AM, Martin G, Schlunck G, Agostini HT, Klagsbrun M, Smith LE, Sapieha P, Stahl A. Semaphorin 3F forms an anti-angiogenic barrier in outer retina. *FEBS Lett.* 2013 Jun 5;587(11):1650-5.
36. Takahashi T, Nakamura F, Jin Z, Kalb RG, Strittmatter SM. Semaphorins A and E act as antagonists of neuropilin-1 and agonists of neuropilin-2 receptors. *Nat Neurosci.* 1998 Oct;1(6):487-93.
37. Bentley D, O'Connor TP. Cytoskeletal events in growth cone steering. *Curr Opin Neurobiol.* 1994 Feb;4(1):43-8.
38. Fan J, Raper JA. Localized collapsing cues can steer growth cones without inducing their full collapse. *Neuron.* 1995 Feb;14(2):263-74.
39. Hall A, Lalli G. Rho and ras GTPases in axon growth, guidance, and branching. *Cold Spring Harb Perspect Biol.* 2010 Feb;2(2):a001818.
40. Dickson BJ. Rho GTPases in growth cone guidance. *Curr Opin Neurobiol.* 2001 Feb;11(1):103-10.
41. Luo L. Rho GTPases in neuronal morphogenesis. *Nat Rev Neurosci.* 2000 Dec;1(3):173-80.
42. Liu BP, Strittmatter SM. Semaphorin-mediated axonal guidance via rho-related G proteins. *Curr Opin Cell Biol.* 2001;13(5):619-26.
43. Rohm B, Rahim B, Kleiber B, Hovatta I, Püschel AW. The semaphorin 3A receptor may directly regulate the activity of small GTPases. *FEBS Lett.* 2000;486(1):68-72.
44. Oinuma I, Ishikawa Y, Katoh H, Negishi M. The semaphorin 4D receptor plexin-B1 is a GTPase activating protein for R-ras. *Science.* 2004 Aug 6;305(5685):862-5.
45. Negishi M, Oinuma I, Katoh H. R-ras as a key player for signaling pathway of plexins. *Mol Neurobiol.* 2005 Dec;32(3):217-22.
46. Guttman-Raviv N, Shraga-Heled N, Varshavsky A, Guimaraes-Sternberg C, Kessler O, Neufeld G. Semaphorin-3A and semaphorin-3F work together to

Competing interests: None declared. Conflict of interests: None declared.  
 All authors contributed to conception and design, manuscript preparation, read and approved the final manuscript.  
 All authors abide by the Association for Medical Ethics (AME) ethical rules of disclosure.



- repel endothelial cells and to inhibit their survival by induction of apoptosis. *J Biol Chem.* 2007 Sep 7;282(36):26294-305.
47. Yu W, Bai Y, Han N, Wang F, Zhao M, Huang L, Li X. Inhibition of pathological retinal neovascularization by semaphorin 3A. *Mol Vis.* 2013 Jun 27;19:1397-405.
48. Sakurai A, Doçi CL, Doci C, Gutkind JS. Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer. *Cell Res.* 2012;22(1):23-32.
49. Geretti E, Shimizu A, Klagsbrun M. Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis. *Angiogenesis.* 2008;11(1):31-9.
50. Neufeld G, Kessler O. The semaphorins: Versatile regulators of tumour progression and tumour angiogenesis. *Nature reviews.Cancer.* 2008;8(8):632-45.
51. Behar O, Golden JA, Mashimo H, Schoen FJ, Fishman MC. Semaphorin III is needed for normal patterning and growth of nerves, bones and heart. *Nature.* 1996 Oct 10;383(6600):525-8.
52. Feiner L, Webber AL, Brown CB, Lu MM, Jia L, Feinstein P, Mombaerts P, Epstein JA, Raper JA. Targeted disruption of semaphorin 3C leads to persistent truncus arteriosus and aortic arch interruption. *Development.* 2001 Aug;128(16):3061-70.
53. Kagoshima M, Ito T. Diverse gene expression and function of semaphorins in developing lung: Positive and negative regulatory roles of semaphorins in lung branching morphogenesis. *Genes Cells.* 2001 Jun;6(6):559-71.
54. Serini G, Maione F, Giraudo E, Bussolino F. Semaphorins and tumor angiogenesis. *Angiogenesis.* 2009;12(2):187-93.
55. Kigel B, Varshavsky A, Kessler O, Neufeld G. Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells. *PLoS One.* 2008 Sep 26;3(9):e3287.
56. Bielenberg DR, Klagsbrun M. Targeting endothelial and tumor cells with semaphorins. *Cancer Metastasis Rev.* 2007;26(3-4):421-31.
57. Neufeld G, Lange T, Varshavsky A, Kessler O. Semaphorin signaling in vascular and tumor biology. *Adv Exp Med Biol.* 2007;600:118-31.
58. Takamatsu H, Kumanogoh A. Diverse roles for semaphorin-plexin signaling in the immune system. *Trends Immunol.* 2012;33(3):127-35.
59. Hayashi M, Nakashima T, Taniguchi M, Kodama T, Kumanogoh A, Takayanagi H. Osteoprotection by semaphorin 3A. *Nature.* 2012 May 3;485(7396):69-74.
60. Harada S, Nagy JA, Sullivan KA, Thomas KA, Endo N, Rodan GA, Rodan SB. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. *J Clin Invest.* 1994 Jun;93(6):2490-6.
61. Gonzalez AM, Buscaglia M, Ong M, Baird A. Distribution of basic fibroblast growth factor in the 18-day rat fetus: Localization in the basement membranes of diverse tissues. *J Cell Biol.* 1990 Mar;110(3):753-65.
62. Gelb DE, Rosier RN, Puzas JE. The production of transforming growth factor-beta by chick growth plate chondrocytes in short term monolayer culture. *Endocrinology.* 1990 Oct;127(4):1941-7.
63. Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. *Proc Natl Acad Sci U S A.* 1990 Sep;87(17):6624-8.
64. Gagliardini V, Fankhauser C. Semaphorin III can induce death in sensory neurons. *Mol Cell Neurosci.* 1999 Oct-Nov;14(4-5):301-16.
65. Ben-Zvi A, Yagil Z, Hagalili Y, Klein H, Lerman O, Behar O. Semaphorin 3A and neurotrophins: A balance between apoptosis and survival signaling in embryonic DRG neurons. *J Neurochem.* 2006 Jan;96(2):585-97.
66. Davies Cde L, Melder RJ, Munn LL, Mouta-Carreira C, Jain RK, Boucher Y. Decorin inhibits endothelial migration and tube-like structure formation: Role of thrombospondin-1. *Microvasc Res.* 2001 Jul;62(1):26-42.
67. Moses MA, Wiederschain D, Wu I, Fernandez CA, Ghazizadeh V, Lane WS, Flynn E, Sytkowski A, Tao T, Langer R. Troponin I is present in human cartilage and inhibits angiogenesis. *Proc Natl Acad Sci U S A.* 1999 Mar 16;96(6):2645-50.
68. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. *Cell.* 1997 Jan 24;88(2):277-85.
69. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, Que I, Lowik C, Timpl R, Olsen BR. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. *EMBO J.* 1999 Aug 16;18(16):4414-23.
70. Takahashi K, Saishin Y, Saishin Y, Silva RL, Oshima Y, Oshima S, Melia M, Paszkiet B, Zerby D, Kadan MJ, Liao G, Kaleko M, Connelly S, Luo T, Campochiaro PA. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. *FASEB J.* 2003 May;17(8):896-8.
71. Pufe T, Petersen WJ, Miosge N, Goldring MB, Mentlein R, Varoga DJ, Tillmann BN. Endostatin/collagen XVIII--an inhibitor of angiogenesis--is expressed in cartilage and fibrocartilage. *Matrix Biol.* 2004 Aug;23(5):267-76.
72. Kim YM, Hwang S, Kim YM, Pyun BJ, Kim TY, Lee ST, Gho YS, Kwon YG. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. *J Biol Chem.* 2002 Aug 2;277(31):27872-9.
73. Petersen W, Tsokos M, Pufe T. Expression of VEGF121 and VEGF165 in hypertrophic chondrocytes of the human growth plate and epiphyseal cartilage. *J Anat.* 2002 Aug;201(2):153-7.
74. Pfander D, Kortje D, Zimmermann R, Weseloh G, Kirsch T, Gesslein M, Cramer T, Swoboda B. Vascular endothelial growth factor in articular cartilage of healthy and osteoarthritic human knee joints. *Ann Rheum Dis.* 2001 Nov;60(11):1070-3.
75. Enomoto H, Inoki I, Komiya K, Shiomi T, Ikeda E, Obata K, Matsumoto H, Toyama Y, Okada Y. Vascular

Competing interests: None declared. Conflict of interests: None declared.  
 All authors contributed to conception and design, manuscript preparation, read and approved the final manuscript.  
 All authors abide by the Association for Medical Ethics (AME) ethical rules of disclosure.

Licensee OAPL (UK) 2014. Creative Commons Attribution License (CC-BY)

FOR CITATION PURPOSES: Binch ALA, Cross AK, Le Maitre CL. The regulation of nerve and blood vessel ingrowth in aneural and avascular intervertebral disc and articular cartilage. *OA Arthritis* 2014 Feb 10;2(1):4.



- endothelial growth factor isoforms and their receptors are expressed in human osteoarthritic cartilage. *Am J Pathol.* 2003 Jan;162(1):171-81.
76. Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW, Lee ST, Kwon YG. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. *Cancer Res.* 2000 Oct 1;60(19):5410-3.
77. Pufe T, Harde V, Petersen W, Goldring MB, Tillmann B, Mentlein R. Vascular endothelial growth factor (VEGF) induces matrix metalloproteinase expression in immortalized chondrocytes. *J Pathol.* 2004 Mar;202(3):367-74.
78. Pufe T, Mentlein R, Tsokos M, Steven P, Varoga D, Goldring MB, Tillmann BN, Paulsen FP. VEGF expression in adult permanent thyroid cartilage: Implications for lack of cartilage ossification. *Bone.* 2004 Aug;35(2):543-52.
79. Lyons G, Eisenstein SM, Sweet MB. Biochemical changes in intervertebral disc degeneration. *Biochim Biophys Acta.* 1981 Apr 3;673(4):443-53.
80. Antoniou J, Goudsouzian NM, Heathfield TF, Winterbottom N, Steffen T, Poole AR, Aebi M, Alini M. The human lumbar endplate. evidence of changes in biosynthesis and denaturation of the extracellular matrix with growth, maturation, aging, and degeneration. *Spine (Phila Pa 1976).* 1996 May 15;21(10):1153-61.
81. Le Maitre CL, Freemont AJ, Hoyland JA. Localization of degradative enzymes and their inhibitors in the degenerate human intervertebral disc. *J Pathol.* 2004 Sep;204(1):47-54.
82. Moos V, Fickert S, Muller B, Weber U, Sieper J. Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage. *J Rheumatol.* 1999 Apr;26(4):870-9.
83. Schlaak JF, Pfers I, Meyer Zum Buschenfelde KH, Marker-Hermann E. Different cytokine profiles in the synovial fluid of patients with osteoarthritis, rheumatoid arthritis and seronegative spondylarthropathies. *Clin Exp Rheumatol.* 1996 Mar-Apr;14(2):155-62.
84. Le Maitre CL, Hoyland JA, Freemont AJ. Catabolic cytokine expression in degenerate and herniated human intervertebral discs: IL-1beta and TNFalpha expression profile. *Arthritis Res Ther.* 2007;9(4):R77.
85. Le Maitre CL, Freemont AJ, Hoyland JA. The role of interleukin-1 in the pathogenesis of human intervertebral disc degeneration. *Arthritis Res Ther.* 2005;7(4):R732-45.
86. Le Maitre CL, Pockert A, Buttle DJ, Freemont AJ, Hoyland JA. Matrix synthesis and degradation in human intervertebral disc degeneration. *Biochem Soc Trans.* 2007 Aug;35(Pt 4):652-5.
87. Purmessur D, Walter BA, Roughley PJ, Laudier DM, Hecht AC, Iatridis J. A role for TNFalpha in intervertebral disc degeneration: A non-recoverable catabolic shift. *Biochem Biophys Res Commun.* 2013 Mar 29;433(1):151-6.
88. Ahn SH, Cho YW, Ahn MW, Jang SH, Sohn YK, Kim HS. mRNA expression of cytokines and chemokines in herniated lumbar intervertebral discs. *Spine (Phila Pa 1976).* 2002 May 1;27(9):911-7.
89. Andrade P, Hoogland G, Garcia MA, Steinbusch HW, Daemen MA, Visser-Vandewalle V. Elevated IL-1beta and IL-6 levels in lumbar herniated discs in patients with sciatic pain. *Eur Spine J.* 2013 Apr;22(4):714-20.
90. Takahashi H, Suguro T, Okazima Y, Motegi M, Okada Y, Kakiuchi T. Inflammatory cytokines in the herniated disc of the lumbar spine. *Spine (Phila Pa 1976).* 1996 Jan 15;21(2):218-24.
91. Burke JG, Watson RW, McCormack D, Dowling FE, Walsh MG, Fitzpatrick JM. Intervertebral discs which cause low back pain secrete high levels of proinflammatory mediators. *J Bone Joint Surg Br.* 2002 Mar;84(2):196-201.
92. Weiler C, Nerlich AG, Bachmeier BE, Boos N. Expression and distribution of tumor necrosis factor alpha in human lumbar intervertebral discs: A study in surgical specimen and autopsy controls. *Spine (Phila Pa 1976).* 2005 Jan 1;30(1):44,53; discussion 54.
93. Phillips KL, Jordan-Mahy N, Nicklin MJ, Le Maitre CL. Interleukin-1 receptor antagonist deficient mice provide insights into pathogenesis of human intervertebral disc degeneration. *Ann Rheum Dis.* 2013 Nov 1;72(11):1860-7.
94. Demircan K, Hirohata S, Nishida K, Hatipoglu OF, Oohashi T, Yonezawa T, Apte SS, Ninomiya Y. ADAMTS-9 is synergistically induced by interleukin-1beta and tumor necrosis factor alpha in OUMS-27 chondrosarcoma cells and in human chondrocytes. *Arthritis Rheum.* 2005 May;52(5):1451-60.
95. Pockert AJ, Richardson SM, Le Maitre CL, Lyon M, Deakin JA, Buttle DJ, Freemont AJ, Hoyland JA. Modified expression of the ADAMTS enzymes and tissue inhibitor of metalloproteinases 3 during human intervertebral disc degeneration. *Arthritis Rheum.* 2009 Feb;60(2):482-91.
96. Cs-Szabo G, Ragasa-San Juan, Turumella V, Masuda K, Thonar EJ, An HS. Changes in mRNA and protein levels of proteoglycans of the anulus fibrosus and nucleus pulposus during intervertebral disc degeneration. *Spine.* 2002 10/15;27(1528-1159; 20):2212-9.
97. Inkinen RI, Lammi MJ, Lehmonen S, Puustjarvi K, Kaapa E, Tammi MI. Relative increase of biglycan and decorin and altered chondroitin sulfate epitopes in the degenerating human intervertebral disc. *J Rheumatol.* 1998 Mar;25(3):506-14.
98. Eyre DR, Muir H. Quantitative analysis of types I and II collagens in human intervertebral discs at various ages. *Biochim Biophys Acta.* 1977 May 27;492(1):29-42.
99. Hayami T, Funaki H, Yaoeda K, Mitui K, Yamagiwa H, Tokunaga K, Hatano H, Kondo J, Hiraki Y, Yamamoto T, Duong le T, Endo N. Expression of the cartilage derived anti-angiogenic factor chondromodulin-I decreases in the early stage of experimental osteoarthritis. *J Rheumatol.* 2003 Oct;30(10):2207-17.
100. Wagstaff S, Smith OV, Wood PH. Verbal pain descriptors used by patients with arthritis. *Ann Rheum Dis.* 1985;44(4):262-5.



101. Le Maitre CL, Hoyland JA, Freemont AJ. Interleukin-1 receptor antagonist delivered directly and by gene therapy inhibits matrix degradation in the intact degenerate human intervertebral disc: An in situ zymographic and gene therapy study. *Arthritis Res Ther.* 2007;9(4):R83.
102. Ohtori S, Inoue G, Ito T, Koshi T, Ozawa T, Doya H, Saito T, Moriya H, Takahashi K. Tumor necrosis factor-immunoreactive cells and PGP 9.5-immunoreactive nerve fibers in vertebral endplates of patients with discogenic low back pain and modic type 1 or type 2 changes on MRI. *Spine (Phila Pa 1976).* 2006 Apr 20;31(9):1026-31.
103. Aoki Y, Ohtori S, Takahashi K, Ino H, Takahashi Y, Chiba T, Moriya H. Innervation of the lumbar intervertebral disc by nerve growth factor-dependent neurons related to inflammatory pain. *Spine (Phila Pa 1976).* 2004 May 15;29(10):1077-81.
104. Walsh DA, Hu DE, Mapp PI, Polak JM, Blake DR, Fan TP. Innervation and neurokinin receptors during angiogenesis in the rat sponge granuloma. *Histochem J.* 1996 Nov;28(11):759-69.
105. Aoki M, Tamai K, Saotome K. Substance P- and calcitonin gene-related peptide-immunofluorescent nerves in the repair of experimental bone defects. *Int Orthop.* 1994 Oct;18(5):317-24.
106. Gruber HE, Ingram JA, Hoelscher G, Zinchenko N, Norton HJ, Hanley EN, Jr. Brain-derived neurotrophic factor and its receptor in the human and the sand rat intervertebral disc. *Arthritis Res Ther.* 2008;10(4):R82.
107. Gigante A, Bevilacqua C, Pagnotta A, Manzotti S, Toesca A, Greco F. Expression of NGF, trka and p75 in human cartilage. *Eur J Histochem.* 2003;47(4):339-44.
108. Abe Y, Akeda K, An HS, Aoki Y, Pichika R, Muehleman C, Kimura T, Masuda K. Proinflammatory cytokines stimulate the expression of nerve growth factor by human intervertebral disc cells. *Spine (Phila Pa 1976).* 2007 Mar 15;32(6):635-42.
109. Purmessur D, Freemont AJ, Hoyland JA. Expression and regulation of neurotrophins in the nondegenerate and degenerate human intervertebral disc. *Arthritis Res Ther.* 2008;10(4):R99.
110. Gruber HE, Hoelscher GL, Bethea S, Hanley EN, Jr. Interleukin 1-beta upregulates brain-derived neurotrophic factor, neurotrophin 3 and neuropilin 2 gene expression and NGF production in annulus cells. *Biotech Histochem.* 2012 Nov;87(8):506-11.
111. Gruber HE, Hoelscher GL, Ingram JA, Hanley EN, Jr. Genome-wide analysis of pain-, nerve- and neurotrophin -related gene expression in the degenerating human annulus. *Mol Pain.* 2012 Sep 10;8:63,8069-8-63.
112. Lee JM, Song JY, Baek M, Jung HY, Kang H, Han IB, Kwon YD, Shin DE. Interleukin-1beta induces angiogenesis and innervation in human intervertebral disc degeneration. *J Orthop Res.* 2011 Feb;29(2):265-9.
113. Krock E, Rosenzweig DH, Chabot-Dore AJ, Jarzem P, Weber MH, Ouellet JA, Stone LS, Haglund L. Painful, degenerating intervertebral discs up-regulate neurite sprouting and CGRP through nociceptive factors. *J Cell Mol Med.* 2014 Mar 20
114. Richardson SM, Doyle P, Minogue BM, Gnanalingham K, Hoyland JA. Increased expression of matrix metalloproteinase-10, nerve growth factor and substance P in the painful degenerate intervertebral disc. *Arthritis Res Ther.* 2009;11(4):R126.
115. Azzolina A, Guarneri P, Lampiasi N. Involvement of p38 and JNK MAPKs pathways in substance P-induced production of TNF-alpha by peritoneal mast cells. *Cytokine.* 2002 Apr 21;18(2):72-80.
116. Orita S, Ohtori S, Nagata M, Horii M, Yamashita M, Yamauchi K, Inoue G, Suzuki M, Eguchi Y, Kamoda H, Arai G, Ishikawa T, Miyagi M, Ochiai N, Kishida S, Takaso M, Aoki Y, Takahashi K. Inhibiting nerve growth factor or its receptors downregulates calcitonin gene-related peptide expression in rat lumbar dorsal root ganglia innervating injured intervertebral discs. *J Orthop Res.* 2010 Dec;28(12):1614-20.
117. Witonski D, Wagrowska-Danilewicz M, Raczynska-Witonska G. Distribution of substance P nerve fibers in osteoarthritis knee joint. *Pol J Pathol.* 2005;56(4):203-6.
118. Ohtori S, Takahashi K, Chiba T, Yamagata M, Sameda H, Moriya H. Substance P and calcitonin gene-related peptide immunoreactive sensory DRG neurons innervating the lumbar intervertebral discs in rats. *Ann Anat.* 2002;184(3):235-40.
119. Toyofuku T, Yoshida J, Sugimoto T, Zhang H, Kumanogoh A, Hori M, Kikutani H. FARP2 triggers signals for Semaphorin 3A-mediated axonal repulsion. *Nat Neurosci.* 2005 Dec;8(12):1712-9.
120. Puschel AW. GTPases in semaphorin signaling. *Adv Exp Med Biol.* 2007;600:12-23.
121. Pasterkamp RJ. R-ras fills another GAP in semaphorin signalling. *Trends Cell Biol.* 2005 Feb;15(2):61-4.

Competing interests: None declared. Conflict of interests: None declared.  
 All authors contributed to conception and design, manuscript preparation, read and approved the final manuscript.  
 All authors abide by the Association for Medical Ethics (AME) ethical rules of disclosure.